Peano, Sergio,Broly, Herve,Ponce Jr., Raphael A.,Graffner, Hans Otto Lennart
申请号：
AU2008312406
公开号：
AU2008312406B2
申请日:
2008.10.16
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
The invention relates to novel combination therapies involving BLyS or BLyS/APRILinhibition and anti-CD20 agents for the treatment of autoimmune diseases. Onepreferred method is where the BLyS antagonist is a Fc-fusion protein which canbe a TACI-Fc-fusion protein comprising the extracellular domain of TACI or afunctional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellulardomain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion proteincomprising the extracellular domain of BCMA or a functional fragment thereof.In the methods of the present invention some of anti-CD20 agents contemplatedinclude RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015,and DXL625, although any agent that binds to CD 20 may be suitable. The methodsof the present invention reduce the levels of B cells in patients in need of suchreduction, such as those suffering from autoimmune diseases.
